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Nanomaterials andNeurodegeneration
Lucia Migliore,* Chiara Uboldi, Sebastiano Di Bucchianico, and
Fabio Coppede'
Medical Genetics Unit, Department of Translational Research and
New Technologies in Medicine and Surgery, University of Pisa, Via Roma,
55 - 56126 Pisa, Italy
The increasing application of nanotechnology in
various industrial, environmental, and human
settings raises questions surrounding the poten-
tial adverse effects induced by nanosized mate-
rials to human health, including the possible
neurotoxic and neuroinflammatory properties of
those substances and their capability to induce
neurodegeneration. In this review, a panel of
metal oxide nanoparticles (NPs), namely tita-
nium dioxide, silicon dioxide, zinc oxide, cop-
per oxide, iron NPs, and carbon nanotubes
have been focused. An overview has been pro-
vided of the in vitro and in vivo evidence of
adverse effects to the central nervous system.
Research indicated that these nanomaterials
(NMs) not only reach the brain, but also can
cause a certain degree of brain tissue damage,
including cytotoxicity, genotoxicity, induction of
oxidative stress, and inflammation, all potentially
involved in the onset and progression of neuro-
degeneration. Surface chemistry of the NMs
may play an important role in their localization
and subsequent effects on the brain of rodents.
In addition, NM shape differences may induce
varying degrees of neurotoxicity. However, one
of the potential biomedical applications of NMs
is nanodevices for early diagnostic and novel
therapeutic approaches to counteract age
related diseases. In this context, engineered
NMs were promising vehicles to carry diagnos-
tic and therapeutic compounds across the
blood–brain barrier, thereby representing very
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INTRODUCTION
Nanomaterials are small molecules with distinct biolog-
ical activity that have been progressively and increasingly
applied in various industrial and medical settings over the
last 30 years [Robertson et al., 2010; Schr€ofel et al.,
2014; ShannahAn et al., 2012]. However, despite great
progress in nanotechnologies, comparatively little is
known to date on the negative effects that exposure to
NMs may have on the human brain, including the poten-
tial induction of pathways leading to neurodegeration
[Cupaioli et al., 2014]. Although many NMs exhibit
potential benefits for diagnostic and therapeutic purposes,
some of these molecules can exert unfavorable effects,
suggesting that the beneficial and harmful effects should
be compared prior to their application to humans [Iqbal
et al., 2013]. Indeed, NMs can enter the human body
through several routes, including absorption through the
skin or the digestive tract, inhalation, and blood injection.
NMs may cross the blood–brain barrier (BBB) to reach
the central nervous system (CNS), where they have been
suspected to impair several molecular pathways and con-
tribute to neurodegeration [Iqbal et al., 2013; Cupaioli
et al., 2014].
Neurodegenerative diseases are a heterogeneous
group of either hereditary or sporadic conditions all
characterized by progressive nervous system dysfunc-
tion resulting from the degeneration of selected neurons
in the CNS. Some of the most well known neurodege-
nerative diseases are Alzheimer’s disease (AD) and
other dementias, Parkinson’s disease (PD), amyotrophic
lateral sclerosis (ALS), and Huntington’s disease (HD)
[Migliore and Coppede`, 2009]. Despite the heterogene-
ous nature of neurodegenerative diseases, the applica-
tion of recent genome-wide and -omics approaches has
provided novel insights into the critical molecular path-
ways of those disorders, revealing that aggregation and
accumulation of misfolded proteins, mitochondrial dys-
function, oxidative stress, oxidatively damaged DNA
and impaired DNA repair, apoptosis, impaired
autophagy-lysosomal activities, inflammation and micro-
glia activation, perturbation of vesicle trafficking and
synapse dysfunction, RNA processing and protein deg-
radation pathways, as well as epigenetic deregulation of
gene expression, are common pathways in neurodege-
nerative diseases [Coppede` and Migliore, 2010; Gior-
dano et al., 2013; Golde et al., 2013; Ramanan and
Saykin, 2013; Vanderweyde et al., 2013; Amor et al.,
2014; B€aumer et al., 2014].
Recent evidence indicates that NPs can impair dopami-
nergic and serotoninergic systems, the former being rele-
vant for PD and the latter for AD pathogenesis, and can
cause changes of neuronal morphology and cell death. In
addition, NPs can also contribute to neurodegeneration by
inducing mitochondrial dysfunction, redox imbalance and
apoptosis, autophagy and impaired lysosomal activity,
cytoskeletal damage and vesicle trafficking perturbations,
neuroinflammation, and microglia activation [Iqbal et al.,
2013; Cupaioli et al., 2014]. Furthermore, in vitro evi-
dence suggests that engineered NMs are able to induce
changes in the expression of genes involved in DNA
methylation pathways, as well as global changes in epige-
netic marks such as DNA methylation and histone tail
modifications, all potentially involved in human complex
disorders, including neurodegeneration [Stoccoro et al.,
2013].
Conversely, since biodegradable NMs can be engi-
neered to load drugs, contrast agents, and cellular or
intracellular component targeting moieties, they have
emerged as potential alternatives for tracking and treating
human diseases, including neurodegenerative disorders
[Marrache et al., 2013]. Nanoparticulate drug carriers are
able to cross the BBB by virtue of their size, surface
potential, or surface coatings, and are currently under
investigation for effective delivery of pharmaceuticals or
contrast agents active in the treatment and detection of
AD and other neurodegenerative diseases [Garbayo et al.,
2013; Oesterling et al., 2014]. Indeed, during the past
decade, nanotechnology has been widely considered as a
promising tool for theranosis (diagnosis and therapy) of
neurodegenerative diseases [Amiri et al., 2013]. The aim
of this review is to critically discuss available in vitro
and in vivo data on the potential neurotoxic effects of
NMs in the context of neurodegeneration, with a focus on
the induction of cytotoxic and genotoxic effects, oxidative
stress, and inflammatory pathways. Moreover, we also
provide some examples of the potential beneficial uses of
NMs in the context of diagnosis and treatment of neuro-
degenerative diseases.
CYTOTOXIC,GENOTOXIC,OXIDATIVE, AND
INFLAMMATORY POTENTIALOFNMS: IMPLICATIONS FOR
NEURODEGENERATION
Due to their unique physico-chemical properties (i.e.,
small size, large surface area, composition, and function-
alization) several types of metallic NPs are able to cross
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the BBB and interact with the CNS components. How-
ever, despite the large number of both in vitro and in
vivo investigations performed so far, the interactions
between NMs and the CNS are still not completely under-
stood and their toxic potential is still unclear. The major-
ity of the data available in the literature report that
metallic NPs induce toxic effects to the target cells or to
the exposed animals, and the toxicity is mainly triggered
via oxidative stress. The evidence that NMs induce cyto-
toxicity and genotoxicity, as well as oxidative stress and
inflammation in various cell lines representative of body
compartments such as the respiratory system, the intes-
tine, and the immune system, amplifies the need for com-
prehensive studies on the neurotoxicity and the
neurodegeneration induced by NMs engineered for the
screening, diagnosis, and therapy of CNS diseases. More-
over, the evidence that the CNS is a potential susceptible
target for nanosized materials and that NMs can penetrate
there through the olfactory bulb and deposit in the hippo-
campus [Oberd€orster et al., 2004; Wang et al., 2008] fur-
ther emphasizes the need for studies on the potential
neuronal effects of NMs. Retention of particles in the
CNS, neurotoxicity, apoptosis, and oxidative stress, as
well as changes in gene expression and neuropathological
lesions are the most investigated parameters. The next
sections discuss the evidence available on the most
widely used NMs in industrial or biomedical applications,
and provide a summary of in vitro (Table I) and in vivo
(Table II) studies.
Titanium Dioxide Nanoparticles
Titanium dioxide nanoparticles (TiO2 NPs) are one of
the most frequently used NPs in industrial applications,
ranging from paints to ceramics and from food to cosmet-
ics. Therefore, investigation of risks associated with occu-
pational exposure to TiO2 NPs is of pivotal interest.
However, the neurotoxic potential of these NPs has only
recently been examined.
Among the first studies to demonstrate the cytotoxic
effects of TiO2 micro- and nanoparticles on human neural
cells (U87 astrocytoma cells) as well as in human fibro-
blasts (HFF-1 cells), were Lai et al. [2008]. Both TiO2
microparticles (1–1.3 l particle size) and nanoparticles
(<25 nm) were able to induce cell death in both human
cell types, with mechanisms including apoptosis, necrosis,
and possibly apoptosis-like and necrosis-like cell death
types [Lai et al., 2008]. Subsequently, Marquez-Ramırez
et al. [2012] demonstrated that the in vitro proliferation
of murine C6 and human U373 glial cells was linearly
inhibited in the presence of 40–200 nm TiO2 NPs, with
apoptosis induced 96 hr after exposure. Moreover, TiO2
NPs were internalized in cytoplasmic vesicles and
induced morphological changes, observable after just 24
hr of incubation [Marquez-Ramırez et al., 2012]. The tox-
icity of TiO2 NPs to the same C6 and U373 cells was fur-
ther confirmed by Huerta-Garcıa et al. [2014]. They used
immunostaining to observe the morphological changes
exerted by titania, including impairment of the integrity
of mitochondria. In addition, severe changes in the redox-
state of the cells and in lipid peroxidation, accompanied
by increased levels of glutathione peroxidase, catalase,
and superoxide dismutase, demonstrated that TiO2 NPs
induced oxidative stress in rat and human microglial cells
[Huerta-Garcıa et al., 2014]. The ability of TiO2 NPs to
induce oxidative stress had already been previously
reported in the murine microglial cell line BV-2, where
the release of free radicals occurred less than 5 min after
exposure to subtoxic concentrations of Degussa P25 nano-
particles [Long et al., 2006]. In addition, the prolonged (2
hr) release of reactive oxygen species (ROS) suggested
that TiO2 NPs interfered with the mitochondrial apparatus
of BV-2 cells [Long et al., 2006]. Further investigations
were performed to test the ability of TiO2 NPs to cause
inflammation and microglia-mediated neurotoxicity. Xue
et al. [2012] demonstrated that exposure of Sprague-
Dawley rat freshly isolated microglia cells to TiO2 NPs
enhanced the release of nitric oxide (NO) via upregula-
tion of the expression of inducible nitric oxide synthase
(iNOS), both at the mRNA and protein levels. Moreover,
the inflammation produced by TiO2 NPs led to increased
expression of monocyte chemoattractant protein-1 (MCP-
1) and macrophage inflammatory protein 1 alpha (MIP-
1a), while secretion of TNF-a, IL-1ß, and IL-6 was sig-
nificantly enhanced upon exposure to titania. Finally, to
test if TiO2 NPs were able to initiate microglia-mediated
neurodegeneration, the rat embryonic pheochromocytoma
cell line PC12 was incubated with supernatants of the
exposed microglial cells. The inflammatory cytokines
TNF-a, IL-1ß, and IL-6 contained in the supernatant
from TiO2 NP-treated microglia impaired the viability of
PC12 and severely suppressed the expression of the tyro-
sine hydroxylase (Th) gene, which is involved in the
dopamine (DA) secretion in the CNS [Xue et al., 2012].
The impact of the crystalline structure of TiO2 NPs on
neurodegeneration has also been explored. Since TiO2
NPs can mainly occur in the anatase and rutile forms, a
comparison of the effects of these two crystalline struc-
tures was performed on PC12 [Wu et al., 2010] and
SHSY5Y [Valdiglesias et al., 2013b] neuronal cells. Ana-
tase TiO2 NPs were more efficient than rutile NPs at gen-
erating a concentration-dependent decrease of cell
viability in PC12 cells. Similarly, membrane damage
evaluated via the lactate dehydrogenase (LDH) release
assay was greater in the presence of anatase TiO2 NPs.
At high doses (200 mg/mL) ROS production was signifi-
cantly higher in PC12 exposed to anatase TiO2 NPs than
to rutile, with similar results observed for the cellular
levels of glutathione (GSH), superoxide dismutase (SOD),
and malondialdehyde (MDA). Furthermore, annexin
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V-FITC and PI staining showed that apoptotic and
necrotic PC12 cells increased significantly with anatase
titania, but flow cytometry demonstrated that both crystal-
line forms were able to arrest the cell cycle in G2/M
phase. Western blot analysis confirmed that anatase TiO2
NPs were more potent than rutile in activating apoptosis
and cell cycle checkpoint proteins: the expression of
JNK, p53, p21, GADD45, as well as bax and bcl-2 was
higher following exposure to anatase NPs than to the
rutile ones [Wu et al., 2010].
In contrast to the above, crystalline forms of TiO2 NPs
had no impact on cytotoxic effects in the human neuroblas-
toma SHSY5Y cell line [Valdiglesias et al., 2013b]. MTT
test and neutral red uptake showed that up to 24 hr exposure
to 0–150 mg/mL pure anatase and P25 (80:20 anatase:rutile)
TiO2 NPs did not impair the viability of SHSY5Y. More-
over, no morphological alterations were observed and elec-
tron microscopy studies showed that TiO2 NPs were
internalized in a time- and concentration-dependent manner,
although pure anatase TiO2 NPs were slightly more effi-
ciently taken up than P25. Additionally, as previously
observed in PC12 cells [Wu et al., 2010], pure anatase TiO2
NPs altered the SHSY5Y cell cycle and induced apoptotic
and necrotic events, while no effects were observed in cells
treated with P25. Interestingly, both types of TiO2 NPs
enhanced the formation of micronuclei and increased pri-
mary, but not oxidatively, damaged DNA observed with the
comet assay [Valdiglesias et al., 2013a, b].
Since TiO2 NPs induced in vitro neurodegeneration, in
vivo studies are critically important to further investigate
the toxic potential of these NPs. To this end, Zhang et al.
[2011a, b, c] focused their attention on the neurological
lesions in the brain of female CD-1 mice induced by
intranasally instilled TiO2 NPs of various size and surface
coating. The results indicated that surface properties play
a role in the neurodegenerative mechanisms of TiO2 NPs:
after 30 days exposure, hydrophobic TiO2 NPs accumu-
lated significantly in the cerebral cortex and in the stria-
tum, while microsized and nano-hydrophilic (silica-
coated) titania did not differ from the unexposed animals.
Moreover, hydrophilic TiO2 NPs caused morphological
changes of neurons in the cerebral cortex. There was also
a significant decrease in norepinephrine (NE) levels in the
hippocampus, cerebral cortex, cerebellum, and striatum
after hydrophilic TiO2 NPs instillation, whereas hydro-
phobic titania did not alter the monoamine neurotransmit-
ter levels in sub-brain regions [Zhang et al., 2011a, b, c].
Shrivastava et al. [2014] exposed Swiss albino mice for
21 days to a single oral dose of TiO2 NPs and observed
enhancement of DA and NE levels. They also detected
oxidative stress conditions with increased ROS and
reduced SOD production, suggesting that TiO2 NPs are
neurotoxic. It is, therefore, interesting to note that muta-
tions of superoxide dismutase 1 (SOD1) cause familial
forms of ALS [Rosen et al., 1993].
Finally, an interesting study was recently performed in
pregnant Wistar rats that received intragastric TiO2 NPs
(100 mg/kg body weight) daily from gestational days
2–21. Exposure to TiO2-NPs significantly reduced cell
proliferation in the hippocampus, and impaired learning
and memory in offspring [Mohammadipour et al., 2014].
The TiO2 NPs assessed in the above in vitro and
in vivo experiments differed according to their crystalline
form (anatase or rutile), surface characteristics, or dose
used. Similarly, the endpoints measured (cell viability,
inflammation, oxidative stress markers, cytogenetic
effects) also differed greatly, complicating direct compari-
sons between studies. Nevertheless, both forms (anatase
and rutile) have been shown to be able to induce neuro-
toxicity at various levels, with the anatase form generally
more active than the rutile form. Taken together the
above findings indicate that single neurons, microglial
cells, and the whole CNS (including brain regions critical
for the onset of neurodegenerative diseases) are poten-
tially susceptible targets for TiO2 NPs.
Silicon Dioxide Nanoparticles
Another type of metal oxide used in industry and pro-
posed for drug and gene delivery is silicon dioxide nano-
particles (SiO2 NPs). The mechanism of toxicity of SiO2
NPs is linked to the overproduction of ROS and to the
activation of pro-inflammatory responses [Liu and Sun,
2010; Park and Park, 2009]. For example, SiO2 NPs
stimulated the secretion of the pro-inflammatory cytokines
TNF-a, IL-1 ß, and IL-6 in freshly isolated rat microglial
cells, but they were not able to stimulate the secretion of
NO, MIP-1a and MCP-1, or NF-jB, which are known to
be involved in the induction of inflammation-related
genes and in microglia activation [Xue et al., 2012].
Using primary microglial cells from Sprague-Dawley
pups, Choi and collaborators reported that SiO2 NPs were
stored intracellularly within phagocytic membrane-bound
vesicles, and that silica induced a significant release of
ROS and nitric oxidative species (NOS) accompanied by
an increased COX-2 gene expression, although the cell
viability was not affected [Choi et al., 2010]. Moreover,
exposure of PC12 neuronal cells to SiO2 NPs revealed a
concentration-dependent decrease in cell viability, deple-
tion of GSH, and enhanced ROS production. In this
study, silica nanoparticles were internalized as agglomer-
ates in the cytoplasm and induced significant morphologi-
cal changes, resulting in cells that appeared small and
fragmented and that had reduced ability to grow neurites,
therefore impeding the development of intercellular con-
tacts and the formation of mature cells [Wang et al.,
2011a, b]. Exposure to low doses (10 lg/mL) of 15 nm
SiO2 NPs similarly led to morphological alterations and
concentration-dependent cytotoxicity in human SK-N-SH
and mouse Neuro2a (N2a), two common neuroblastoma
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cell lines. By electron microscopy, SK-N-SH cells were
shown to be able to internalize silica particles throughout
the cytoplasm, while the particles were found to be stored
within vesicles in N2a cultures [Yang et al., 2014]. In
addition, treatment of SK-N-SH and N2a cells caused
ROS release and significant dose-dependent apoptosis, as
shown by nuclear and TUNEL staining. Interestingly,
Yang et al. [2014] reported that SiO2 NPs (mean particles
size 12.1 nm) increased the deposition of intracellular ß-
amyloid peptide (Aß1–42) due to both the upregulation of
ß-amyloid precursor protein (APP) and the downregula-
tion of the amyloid-ß-degrading enzyme neprylysin, sug-
gesting a possible role for SiO2 NPs in the development
of AD. Indeed, according to the amyloid cascade hypoth-
esis of AD, changes in APP and/or Ab1–42 homeostasis
foster the assembly of Ab peptides into progressively
higher order structures, from dimers all the way up to the
insoluble plaques, which finally deposit in the brain; these
events are sufficient to initiate the pathological and clini-
cal changes of the disease [Hardy and Selkoe, 2002].
The use of SiO2 NPs in many applications and their
potential use for drug and gene delivery, makes it essen-
tial to conduct further studies on possible biological
effects. This is particularly important given that in vitro
studies have shown that SiO2 NPs are cytotoxic [Eom
and Choi, 2009; Akhtar et al., 2010], induce oxidative
stress [Napierska et al., 2009; Zhang et al., 2011a, b, c;
Ahmad et al., 2012; Ahamed, 2013] and inflammatory
responses [Panas et al., 2013; Kusaka et al., 2014; Men-
doza et al., 2014] in many cell types, including cells rep-
resentative of the CNS [Choi et al., 2010;Wang et al.,
2011a, b; Xue et al., 2012; Yang et al., 2014]. Further-
more, SiO2 NPs have been reported to induce inflamma-
tion [Lee et al., 2011; Morishige et al., 2012; Brown
et al., 2014], as well as pulmonary [Choi et al., 2008;
Zhao et al., 2014] and hepatic [Nishimori et al., 2009;
Liu et al., 2012] toxicity in vivo.
Wu et al. [2011] exposed SD rats to intranasal instilla-
tion of SiO2 NPs and observed significant brain accumu-
lation of nanoparticles, oxidative stress (increased H2O2
and MDA and significant decrease in GSH), and
increased TNF-a and IL-1ß levels, indicative of inflam-
mation. Interestingly, when a deeper analysis of the con-
tent of silica in the different brain regions was performed,
it was possible to establish a ranking of SiO2 NPs accu-
mulation that corresponded to olfactory bulb> stria-
tum> hippocampus> brain stem> cerebellum> frontal
cortex [Wu et al., 2011]. In Balb/c mice polyethylene
glycol-coated silica nanoparticles (PEG-SiO2 NPs)
crossed the BBB, showing size-dependent variation in
transport efficiency. At short exposure times (15 min), 50
and 100 nm PEG-SiO2 NPs were poorly able to migrate
through the BBB but their uptake significantly increased
after 60 min. Smaller (25 nm) PEG-SiO2 NPs, in contrast,
were already significantly taken up after a 15 min incuba-
tion, and their migration across the BBB was further
enhanced after 1 hr [Liu et al., 2014]. In addition to BBB
disruption and neuronal damage, SiO2 NPs have also
been associated with behavioral impairment in rats
[Sharma et al., 2013a]. Similarly, silica nanoparticles dis-
turbed the neural behavior of zebrafish Danio rerio in a
size-dependent manner, as 15 nm SiO2 NPs significantly
changed the color preference of the animals and caused
PD-like behavior, neither of which were observed for
50 nm particles [Li et al., 2014].
Overall, both in vitro and in vivo data indicate that
SiO2 NPs can pass through the BBB. The increased pro-
duction of ROS and of pro-inflammatory responses, which
seem a common feature of SiO2 NPs, can adversely affect
different cell types. The major emerging finding is that
transport efficiency of SiO2 NPs across BBB was found
to be size-dependent, with increased particle size resulting
in decreased efficiency. Greater concern is therefore justi-
fied when considering neurotoxicity associated with small
sized silica nanoparticles in biomedical applications and
occupational exposure in large-scale production.
Zinc Oxide Nanoparticles
Zinc oxide nanoparticles (ZnO NPs) are of industrial
interest because of their exceptional optoelectronic, piezo-
electric, ferromagnetic and optical properties. Moreover,
ZnO NPs have been used in sunscreens, biosensors, food
additives, and pigments [Ji and Ye, 2008]. Due to their
antiseptic activity, they also have potential applications in
combatting bacteria-related infections and diseases.
Although some data on the toxic potential of ZnO NPs
are available in the current literature, little is known about
their neurotoxic effects. Deng et al. [2009] showed that in
neural stem cells (NSC), ZnO NPs whose nominal mean
size diameter ranged between 10 and 200 nm impaired
cell viability in a dose-dependent manner. In contrast,
size did not play a role in inducing toxic effects, as a
comparison of the differently sized nanoparticles did not
result in any significant difference in terms of cell viabil-
ity. Electron microscopy analysis and nuclear staining
were used to demonstrate that ZnO NPs induced apopto-
sis in NSC cells [Deng et al., 2009]. Nevertheless, the
authors speculated that the cytotoxicity and apoptosis
induced by ZnO NPs in NSC cells might result from the
zinc ions dissolved either in solution or intracellularly.
This hypothesis was supported also by the fact that the
internalized ZnO NPs were not detectable by electron
microscopy [Deng et al., 2009]. ZnO NPs neurotoxicity
was further evaluated in RSC96 rat Schwann cells com-
paring four different hierarchical structures: monodis-
persed spherical ZnO NPs of 35 nm size, hollow ZnO
microspheres (2.7 mm), prism- (ca., 2.5–6.0 mm in diame-
ter and ca., 18–60 lm in length) and flower-like (500–
600 nm in diameter and several microns in length)
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structures [Yin et al., 2012]. Results demonstrated that
prism- and flower-like ZnO NPs did not induce cytotoxic
effects after 12 hr exposure, while significant impairment
of the viability of RSC96 cells was observed at 48 hr.
Similarly, spherical monodispersed ZnO NPs and zinc
microspheres exerted concentration- and time-dependent
cytotoxicity. Moreover, they significantly enhanced apo-
ptotic events, and G2/M cell cycle arrest was observed
when RSC96 cells were exposed for 12 hr to 80 lg/mL
ZnO nanoparticles and microspheres [Yin et al., 2012].
Interestingly, analysis of the levels of zinc ions performed
in culture media at increasing time points revealed that
the observed time-related ion levels enhancement was the
result of a leaching process occurring during the incuba-
tion period, which suggested that the cytotoxic effects
observed in RSC96 rat Schwann cells were also due to
the ionic fraction in the culture environment and not
exclusively to the nanoparticulated fraction [Yin et al.,
2012].
By confocal microscopy, Kao et al. [2012] observed
that ZnO NPs were internalized in membrane-bound
vesicles in PC12 neuronal cells and caused the reduction
of cell viability and mitochondrial impairment. An exten-
sive study on Zn NPs was performed in the human neuro-
blastoma SHSY5Y cell line, testing several concentrations
and exposure times and employing a battery of cytotoxic-
ity and genotoxicity assays. The internalization of the Zn
NPs was assessed by flow cytometry but it was not possi-
ble to demonstrate that ZnO NPs enter the neuronal cells.
However, a wide range of cytotoxic effects were induced
including apoptosis and cell cycle alterations, as well as
genotoxic effects (micronuclei, H2AX phosphorylation,
and primary and oxidatively damaged DNA), in a dose-
and time-dependent manner [Valdiglesias et al., 2013a].
In vivo, Kao et al. [2012] showed that ZnO NPs intra-
nasally administered to Sprague-Dawley rats (6 hr expo-
sure) translocated into the olfactory bulb and the
synaptosomes, as clearly shown by electron microscopy
micrographs. The translocation of ZnO NPs across the
BBB and into the CNS was further confirmed by Cho
et al. [2013]; after 13 weeks of repeated oral administra-
tion, enhanced ZnO NPs levels were measured in rats
brain compared with the untreated group, although the
uptake was not dose-related. Additionally, ZnO NPs were
reported to disrupt spatial memory and to significantly
impair the synaptic responses of Swiss male mice with
depressive-like behavior [Xie et al., 2012].
In many experimental systems in which Zn NPs were
able to induce neurotoxic effects, there was often no evi-
dence for NP uptake by the cells, and no effect of NP
size on cytotoxicity. Instead, a time-dependent increase of
Zn21 concentration in the culture media was sometimes
found, most likley due to decomposition of ZnO NPs and
the subsequent release of ions, as already reported. How-
ever, the question of whether the increase of intracellular
ions is due to the NPs being taken up by cells, or to NP
dissolution in medium, still remains to be resolved [Van-
debriel and De Jong, 2012].
Copper Oxide Nanoparticles
Copper, an essential trace element vital for the life and
the development of organisms, is known to be involved
in neurodegenerative disorders such as Menkes [Kodama
et al., 201], Wilson’s [Lorincz, 2010], AD, HD, and PD
[Desai and Kaler, 2008; Rivera-Mancia et al., 2010;
Greenough et al., 2013; Montes et al., 2014], acting
through the induction of oxidative stress [Halliwell and
Gutteridge, 1984] and the activation of microglial cells
and inflammation [Zhang et al., 2011b]. Although it is
important to understand how nanosized copper oxide
(CuO NPs) can induce neurotoxicity, to date few investi-
gations have been performed. Wang et al. [2009] investi-
gated expression changes in genes associated with the
dopaminergic system and their correlation with DA deple-
tion in PC12 cells. Treatment with CuO NPs significantly
reduced the content of DA, 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA) in PC12
cells, and induced downregulation in the expression of
the redox-status gene glutathione peroxidase 1 (Gpx1)
and upregulation of thioredoxin reductase 1 gene
(Txnrd1). In addition, CuO NPs upregulated the expres-
sion of the monoamine oxidase A (Maoa), which is
related to DA metabolism, and of the alpha-synuclein
gene (Snca) associated with the pathogenesis of neurode-
generation in PD [Wang et al., 2009]. Indeed, PD results
from loss of neuromelanin-containing dopaminergic neu-
rons in the substantia nigra (SN), with the presence of
eosinophilic, intracytoplasmic inclusions (termed Lewy
bodies) and containing aggregates of a-synuclein as well
as other substances. Furthermore, human SNCA mutations
cause autosomal dominant PD, and SNCA polymorphisms
or epigenetic changes of SNCA gene expression are
believed to contribute to sporadic forms of the disease
[Thomas and Beal, 2011]. An additional study on rat
brain microvessel endothelial rBMECs cells showed that
low concentrations of 40 and 60 nm CuO NPs increased
the cellular proliferation while 50 mg/mL Cu-NPs were
cytotoxic, and the extracellular concentration of the proin-
flammatory mediators Prostaglandin E2 (PGE2), TNF-a,
and IL-1b were significantly increased [Trickler et al.,
2012]. Moreover, Trickler et al. [2012] reported that the
enhanced permeability of rBMEC upon exposure to CuO
NPs suggests that the NPs can be neurotoxic and damage
the BBB even at low doses.
To better investigate their involvement in the etiology
of neurodegenerative disorders, CuO NPs were studied in
vivo. CuO NPs of approximately 50–60 nm mean diame-
ter were able to induce brain dysfunction in rats which,
after 7 days of exposure, exhibited mild cognitive
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impairment and cellular alterations in the brain [Sharma
and Sharma, 2007]. Additionally, intraperitoneal, intrave-
nous, intracarotid or intracerebroventricular administration
of CuO-NPs significantly altered BBB function in several
regions of the brain and spinal cord 24 hr after adminis-
tration, and a marked decrease in local cerebral blood
flow (CBF) and severe brain edema was observed in brain
areas associated with BBB leakage [Sharma et al., 2009].
Moreover, Sharma et al. [2009] observed that the injured
brain areas exhibited neuronal cell damage, glial cell acti-
vation, heat shock protein upregulation and loss of
myelinated fibers, and that these changes were more evi-
dent in mice compared with rats. Furthermore, by means
of Evans blue leakage, it was possible to show that brain
edema formation took place in rats after intravenous,
intraperitoneal and intracerebral administration of CuO
NPs, and that the most severely damaged areas were the
ventral surface of brain and the proximal frontal cortex,
whereas the dorsal surfaces of cerebellum showed mild to
moderate damage [Sharma et al., 2010]. CuO NP treat-
ment also led to detrimental effects on the cognitive func-
tions of Wistar rats, highlighted by poor performance of
animals in behavioral tests. The occurrence of an imbal-
ance in oxidation–antioxidation homeostasis, and of neu-
ronal damage in the hippocampus, suggested the
induction of oxidative damage and neuronal apoptosis
[An et al., 2012]. Despite the scarcity of available studies,
mainly carried out in a few experimental centers, CuO
NPs seem neurotoxic both in vitro and in vivo. Of partic-
ular concern is the finding that nano-CuO can induce
brain dysfunctions and affect the abilities of learning and
memory in rodents.
Silver Nanoparticles
Due to its bactericidal properties and its role as an
imaging contrast agent, silver nanoparticles (Ag NPs) are
promising tools for biomedical applications. It is well
known that the CNS is sensitive to silver [Carpenter,
2001], and that Ag can be retained in the CNS for long
periods of time [Panyala et al., 2008] and induce neuronal
degeneration and BBB malfunction. The ability of Ag
NPs to translocate into the brain by crossing the BBB
was reported in 2010 by Tang et al. Using an in vitro co-
culture model composed of rat brain microvessel endothe-
lial cells and astrocytes, Ag NPs were observed to pass
the BBB by transcytosis and accumulate in endothelial
cells, as shown by electron microscopy [Tang et al.,
2010]. In freshly isolated rat brain microvessel endothelial
rBMEC cells, 25–40–80 nm Ag NPs accumulated in a
dose- and size-dependent manner, and at high concentra-
tions (25–50 mg/cm3) induced an impairment of the cell
viability. Furthermore, size-related morphological changes
and formation of perforations in the monolayer were
observed in rBMECs [Trickler et al., 2010]. In a follow-
up study using confluent porcine brain microvessel endo-
thelial cells, Trickler et al. [2014] observed that 25–40–
80 nm Ag NPs induced pro-inflammatory responses by
enhancing the extracellular levels of PGE2, TNF-a and
IL1ß, in addition to causing BBB leakage and signifi-
cantly higher permeability.
Loss of cytoskeleton structure with degradation of
beta-tubulin and F-actin was observed in primary rat cort-
ical cells exposed to Ag NPs (20 nm mean size diameter),
and phase contrast images showed that Ag NPs inhibited
neuronal extension, neuritic overlap, and impaired the
viability of the rat cortical cells [Xu et al., 2013]. Size-
and time-dependent TNF-a and IL-1ß secretion were
detected, while PGE2 was not released in the presence of
40 and 80 nm Ag NPs. In addition, Ag NPs selectively
affected the permeability of rBMECs: small Ag NPs
(25 nm) induced an increased permeability of fluorescein
across rBMECs, whilst 40 nm Ag NPs only slightly dam-
aged the integrity of the barrier, and 80 nm particles did
not exert any effect [Trickler et al., 2010]. In PC12 cells,
expression changes in genes associated with the dopami-
nergic system were analyzed following exposure to
15 nm Ag NPs: Gpx1 was the only upregulated gene,
whereas there was no change in the expression of genes
related to DA metabolism (Th, Maoa, and Comt) or genes
(Gpr37, Snca and Park2) associated with the pathogenesis
of neurodegeneration in PD [Wang et al., 2009]. In
human-derived SHSY5Y neuroblastoma and D384 astro-
cytoma cells, exposure to 20 nm Ag NPs revealed that at
short exposure times (4–48 hr), Ag NPs induced dose-
and time-dependent impairment of mitochondrial metabo-
lism and cell membrane damage. Similarly, longer expo-
sures (10 days) of SHSY5Y and D384 cells treated with
increasing concentrations of Ag NPs showed dose-
dependent reduction in colony forming efficiency.
Since Ag NPs are known to release silver ions in solu-
tion, a comparison with AgNO3 was performed. Cytotox-
icity was more severe when SHSY5Y and D384 cells
were incubated in the presence of AgNO3 compared with
Ag NPs at both short (4–48 hr) and at long (10 days)
time points [Coccini et al., 2014]. Ziemınska et al. [2014]
investigated the role of Ag NPs in the induction of exci-
totoxicity, a pathological process by which nerve cells are
damaged and killed by excessive stimulation of neuro-
transmitters such as glutamate. Excitotoxicity is linked to
alterations of intracellular calcium levels and deregulation
of intracellular calcium signaling pathways, leading to
ROS production, mitochondrial dysfunction, and ulti-
mately cell death. To this end, primary cultures of rat cer-
ebellar granule cells exposed to Ag NPs activated the
glutamatergic N-methyl-d-aspartate receptors (NMDAR)
and induced calcium imbalance, changes in mitochondrial
membrane potential and significant ROS production, thus
suggesting that Ag NPs have neurotoxic potential
[Ziemınska et al., 2014]. Interestingly, Ziemınska et al.
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[2014] showed that the toxic effects exerted by Ag NPs
were attenuated in the presence of MK-801, a non-
competitive inhibitor of NMDAR.
In vivo studies have demonstrated that Ag NPs accu-
mulate in liver [Kim et al., 2008, 2010] and lungs [Sung
et al., 2009; Song et al., 2013], but Ag NPs are also able
to translocate into the CNS. In fact, 25 nm Ag NPs were
detected by autometallography in the olfactory bulb and
in the lateral brain ventricles of C57BL/6J mice [Genter
et al., 2012], and mass spectrometry showed size-related
internalization of Ag NPs in young ICR mice, with 22–
71 nm particles distributed into the brain, whereas
300 nm Ag NPs were not detected in the tissue after 14
days of oral administration [Park et al., 2010].
Ag NPs (50–60 nm) administered into systemic circula-
tion or brain ventricular spaces of rats and mice showed
severe BBB leakage, formation of brain edema and
decrease in local CBF, as well as glial activation and loss
of myelinated fibers [Sharma et al., 2009]. Size-dependent
BBB breakdown, NOS upregulation, neuronal damage,
and glial fibrillary acidic protein upregulation was
observed in inbred male Sprague-Dawley rats: small Ag
NPs (20–30 nm) induced more severe damage in young
(9–10 weeks old) and old (30–35 weeks old) rats com-
pared with mid-age (18–20 weeks) animals, and the effect
was significantly reduced in the presence of 50–60 and
130–150 nm Ag NPs [Sharma et al., 2013b]. The evi-
dence that very young and old rats showed the most
severe neurodegeneration led Sharma et al. [2013b] to
suggest that children and elderly might be more suscepti-
ble to Ag NPs-induced brain damage.
Altered expression of mouse oxidative stress and anti-
oxidant genes was observed in different regions of
C57BL/6N mice exposed by injection to Ag NPs, sug-
gesting that 25 nm Ag NPs are able to induce oxidative
stress and oxidatively damaged DNA, and could be
involved in the development of neurotoxicity and the
pathogenesis of neurodegenerative disorders [Rahman
et al., 2009].
Silver NPs in solution are known to release Ag-ions
that induce significant toxicity as reported in vitro [Singh
and Ramarao, 2010; Hamilton et al., 2014] and in vivo
[Radniecki et al., 2011; Yang et al., 2012; Visnapuu
et al., 2013]. It is therefore pivotal to understand if the
neurotoxic potential of Ag NPs is due to the nanosized
fraction or to the silver ions, which leached into solution.
When the neurotoxicity induced by Ag NPs and Ag-ions
was compared, interesting results were reported. Hadrup
et al. [2012] observed that in female Wistar rats, 28 days
of 14 nm Ag NPs and silver ions oral administration
induced an increase in DA levels; in contrast, 5-
hydroxytryptamine (5-HT) was enhanced exclusively fol-
lowing exposure to Ag NPs whereas noradrenaline was
upregulated only following exposure to silver ions. Simi-
lar effects were also reported in Wistar Hannover Galas
rats; animals were exposed by repeated oral administra-
tion for 28 days and the analysis of homogenates revealed
that both nanosized and ionic silver accumulated in the
brain with comparable distribution [Loeschner et al.,
2011]. Moreover, silver was detected in brains of 28 days
exposed Sprague-Dawley rats and, while it was elimi-
nated from liver and spleen, a biopersistance of silver
was observed in the brain [van der Zande, 2012]. Interest-
ingly, Ag NPs also were detected in AgNO3 exposed ani-
mals, supporting the evidence that nanoparticles can
originate from Ag-ions in vivo and thus explaining the
fact that Ag NPs and Ag salts exhibited similar distribu-
tion and clearance [van der Zande, 2012]. Additionally,
Dziendzikowska et al. [2012] showed that at short and
mid-term exposures (24 hr and 7 days) the brain was the
organ with the lowest concentration of silver, while a sig-
nificant increase was measured after 28 days Ag NPs
intravenous administration in Wistar rats, demonstrating
that Ag NPs displayed time-dependent deposition in the
brain.
Therefore, based on findings in animals, Ag NPs seem
able to distribute and accumulate over time in many
organs, including the brain. Increasing evidence suggests
that Ag NP-induced neurotoxic effects may occur via sil-
ver ions that are released from the particle surface, as
happens for other metal oxide NPs. A size-dependent
effect was found in vitro and in vivo (small-sized AgNPs
were more active). Moreover, a higher susceptibility in
the age groups most vulnerable (in the younger or older
animals) has been found in vivo.
Magnetic Nanoparticles
The use of magnetic nanoparticles (MNPs) has become
an area of increasing interest in biomedicine. MNPs have
unique features, such as their reaction to a magnetic
force, that can be utilized in drug targeting and cell sort-
ing. Moreover, MNPs have gained interest because of
their potential use as contrast agents for magnetic reso-
nance imaging (MRI) and as heating mediators for hyper-
thermia and cancer therapy [Ito et al., 2005]. However,
their potential neurotoxicity has been poorly investigated.
Au et al. [2007] exposed astrocytes from the cerebral cor-
tices of newborn Sprague-Dawley rats to 10 lg/mL iron
oxide superparamagnetic particles (Fe3O4 or g-Fe2O3)
and reported that although the cell membrane integrity
was not affected, viability and cell adhesion were signifi-
cantly impaired. Anionic magnetic nanoparticles
(AMNPs) were shown to severely affect the viability of
PC12 neuronal cells, and caused morphological alterations
such as reduced microtubules protrusion, reduced forma-
tion of actin microfilaments within the soma, and loss of
organized actin in the cellular body, thus inducing PC12
cells to assume a spheroidal shape [Pisanic et al., 2007].
In rat primary microglia cells, while NO and MCP-1
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production and NF-jB binding activity were comparable
to the untreated control cells, Fe3O4 NPs were found to
exert a mild increase in the expression of the pro-
inflammatory cytokines TNF-a, IL-1ß, and IL-6, indicat-
ing that other inflammatory signaling pathways may act
independently of NF-jB activation [Xue et al., 2012].
However, since significant cytotoxicity in PC12 cells was
not observed following incubation with the supernatant
from Fe3O4 NPs-treated microglia, Xue et al. [2012] con-
cluded that the proinflammatory activity exerted by iron
NPs was not sufficient to cause neurotoxicity and
neurodegeneration.
The interaction of iron oxide nanoparticles (IONPs)
with astrocytes has been extensively investigated, and
Hohnholt et al. [2013] reviewed the main results. Astro-
cytes play an important role in the CNS because they reg-
ulate the metal homeostasis in the brain [Tiffany-
Castiglioni and Qian, 2001; Dringen et al., 2007; Jones,
2012] and protect the brain from metal toxicity and oxi-
dative stress [Hirrlinger and Dringen, 2010; Macco et al.,
2013]. Time- [Geppert et al., 2011], concentration- [Gep-
pert et al., 2011; Hohnholt et al., 2013; Lamkowsky ey
al., 2012] and temperature-dependent [Geppert et al.,
2009; Lamkowsky et al., 2012] accumulation of IONPs
was shown in cultured murine astrocytes, and IONPs
were observed to stably remain in the cells without induc-
ing cytotoxicity [Lamkowsky et al., 2012; Yiu et al.,
2012]. Furthermore, the resistance of astrocytes to IONPs
cytotoxic effects was suggested to be dependent on the
fact that particles are stored in intracellular vesicles and
are not freely dispersed in the cytosol [Hohnholt et al.,
2010; Geppert et al., 2011, 2012], but also the sequestra-
tion of IONPs-leached ions by proteins (such as ferritin)
has a protective effect to the cells [Geppert et al., 2012].
The in vivo uptake and the potential adverse effects of
IONPs in brain have been reviewed by Petters et al.
[2014]. They highlighted that although IONPs are able to
cross the BBB [Kim et al., 2006; Kwon et al., 2008;
Wang et al., 2010, 2011a, b] and induce activation and
the proliferation of microglial cells in the olfactory bulb,
it remains unclear as to under which conditions IONPs
migration occurs, and which regions of the brain are tar-
geted by the particles.
Wu et al. [2013] demonstrated that after 7 days of
intranasal instillation, 30 nm Fe3O4 NPs differentially
deposited in the brain of SD rats; olfactory bulb, striatum
and hippocampus were the regions where IONPs mostly
accumulated compared with brain stem, cerebellum, and
frontal cortex, and the clearance of Fe3O4 NPs from the
brain was slow, as striatum and hippocampus still
retained more than half of IONPs up to 14 days post-
instillation. In addition, Fe3O4 NPs increased the levels of
the oxidative damage markers GSH, H2O2, SOD, and
MDA in the striatum, thus emphasizing the neurotoxic
potential of magnetic NPs [Wu et al., 2013]. Intraneural
injection of maghemite (Fe2O3) and magnetite (Fe3O4)
NPs coated with dimercaptosuccinic acid (DMSA) and
PEG into the sciatic nerve of Sprague-Dawley rats
resulted in an accumulation of macrophages, monocytes,
and lymphocytes at the injection sites, together with
increased levels of ERK, caspase-3, IL1ß, matrix metallo-
peptidase 9 (MMP-9) and heme oxygenase 1 (HO-1),
confirming that IONPs are able to induce oxidative stress,
inflammation and apoptotic events [Kim et al., 2013]. The
accumulation of IONPs and the induction of apoptosis
was also demonstrated in the brain of zebrafish, where
increased levels of ferric iron and enhanced mRNA levels
of caspase-8 (casp8), caspase-9 (casp9) and transcrip-
tional factor AP-1 jun were detected [de Oliveira et al.,
2014].
It is established that magnetic NPs are able to pass
through the BBB and enter the CNS, and that ROS pro-
duction is one of the main mechanisms by which they
induce toxicity in the CNS. A very recent review taking
into account a wide range of toxic effects induced by
IONPs, including neurotoxicity, indicate that surface coat-
ings and particle size seem to be crucial for the observed
IONPs-induced effects [Valdiglesias et al., 2014].
Carbon Nanotubes
Carbon nanotubes (CNT) are a class of NMs whose
structure is exclusively composed of carbon atoms and
which display high electronic and thermal conductivity.
CNTs can occur in two main types: single-walled carbon
nanotubes (SWCNT) consisting of a single sheet of car-
bon benzene rings rolled up into a tubular structure; and
multi-walled carbon nanotubes (MWCNT) consisting of
multiple concentric layers of carbon sheets. The use of
CNTs in biomedicine has grown, due in part to their
improved aqueous dispersibility resulting in some func-
tionalized forms being water dispersible (e.g., carboxy-
lated MWCNT [Ntim et al., 2012]). Nevertheless, our
understanding of the interactions between CNTs and the
CNS, both in vitro and in vivo, remains limited, and their
potential short- and long-term neurotoxicity is still
unclear.
SWCNTs were reported to induce time- and dose-
dependent impairment of cell viability and membrane
damage in PC12 neuronal cells, as well as decrease the
mitochondrial membrane potential. Moreover, SWCNT
induced the formation of ROS, enhanced the levels of
lipid peroxide and decreased SOD, glutathione peroxi-
dase, catalase and GSH in a time- and dose-dependent
manner [Wang et al., 2011b, 2012]. Additionally, PC12
cells exhibited condensed chromatin, fragmented nuclei
and a block of the cell cycle in G2/M phase, indicating
that apoptotic events were enhanced by the exposure to
SWCNT [Wang et al., 2011b]. These effects were pre-
vented by pre-incubation with vitamin E [Wang et al.,
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2012]. CNTs have been proposed as substrates for neuron
growth, and in some experiments have shown toxicity in
cell culture. In order to reduce their toxicity it may be
possible to modify SWCNT surfaces to make the contact
between cells and nanotubes less close. This can be
achieved by enveloping the CNT molecule with surfac-
tants or polymers, such as polypyrrole (PPy). While the
viability of co-cultures of primary embryonic rat hippo-
campal neurons and glial cells was impaired in SWCNT
substrates, toxicity was lower for the PPy-SWCNT-
substrates [Hernandez-Ferrer et al., 2014]. Even the dif-
ferent degrees of agglomeration of SWCNTs can influ-
ence neurotoxicity. In primary mixed neuronal and glial
cells from chicken embryos spinal cord or dorsal root
ganglia, agglomerated SWCNTs significantly decreased
the DNA content and reduced the amount of glial cells,
whereas bundled SWCNT had only mild effects [Belyan-
skaya et al., 2009].
CNTs can retain metal impurities. To test the role of
these impurities in inducing neurotoxicity, MWCNT with
increasing concentrations of iron (Fe-MWCNT) were
investigated in PC12 cells. The results showed that highly
impure Fe-MWCNT impaired cell viability, increased
cytoskeleton disruption, diminished the ability to form
mature neurites and influenced the neuronal dopaminergic
phenotype in NGF-treated rat pheochromocytoma cell
line PC12 cells [Meng et al., 2013].
MWCNTs functionalized with amino groups were
injected into C57/Bl6 mice. The MWCNTs were internal-
ized in microglia, astrocytes and neurons, and stimulated
a transient induction of the pro-inflammatory cytokines
TNF-a, IL-1ß, IL-6, and IL-10 at early time points (<16
hr) [Bardi et al., 2013]. Moreover, the oxidation of nano-
tubes induced significant levels of glial fibrillary acidic
protein (GFAP) and CD11b in the areas of injection, indi-
cating that astrocytes and microglia were locally activated
by MWCNT [Bardi et al., 2013]. In Wistar rats, gadolin-
ium (Gd-SWCNT) and iron (Fe-SWCNT) single-walled
carbon nanotubes were found to accumulate as aggregates
in the cerebral cortex of the brain without altering the tis-
sue architecture nor inducing inflammation [Avti et al.,
2013]. The ability of MWCNT to translocate into the
brain was further demonstrated using C57BL/6J mice,
where monodispersed MWCNT accumulated in the brain
after 12 days of inhalation in a time-related manner [Mer-
cer et al., 2013]. Moreover, 50 nm MWCNTs were
reported to induce brain deformity via an indirect mecha-
nism: MWCNTs crossed the blood-placental barrier of
p531/2 pregnant C57BL/6J mice and induced crown-
shaped tissue malformations of the brain, but they did not
migrate through the BBB as demonstrated by the fact that
CNT did not accumulate in fetal brains [Huang et al.,
2014]. Although CNTs have shown much promise in
many applicative fields, including biomedicine and neuro-
biology, a limited number of studies are available on their
neurotoxicity both in vitro and in vivo. Toxicological
studies performed in vivo have often evaluated the
specificity of many tissues and organs, but the nervous
system was almost never included. Of current interest is
research to identify safer types of CNTs, which should
then be tested in vivo over medium to long periods of
exposure.
USE OFNMS INDIAGNOSIS AND TREATMENTOF
NEURODEGENERATIVE DISEASES
Although different types of evidence have shown that
many NMs can induce toxic mechanisms and cause cyto-
toxicity, genotoxicity, inflammation, and oxidative stress
in vitro and in vivo, the design, development and synthesis
of engineered NMs for biomedical applications is a very
dynamic field. It is expected that engineered NMs will be
used in the screening, diagnosis and treatment of diseases.
However, use of NMs in the diagnosis and treatment of
neurodegenerative diseases implies that NMs migrate
through the BBB, which is known to be tightly regulated
and presents a very low rate of transcytotic vesicles and
acts as a restrictive paracellular diffusion barrier, protect-
ing the neural tissue from toxins and toxicants [Wolburg
and Lippoldt, 2002]. The ability of NMs specifically engi-
neered for the diagnosis and the treatment of neurodege-
nerative diseases to cross the BBB and enter the CNS
depends on the physico-chemical properties of NMs, on
their composition and on their functionalization [Kreuter,
2004]. The use of lipidic (liposomes, nanoemulsions, and
nanocapsules), polymeric (micelles, dendrimers, nanogels,
and polymeric particles), and inorganic (quantum dots and
iron oxide) NMs for CNS targeting, diagnostic, and thera-
peutic purposes was recently reviewed [Modi et al., 2009,
2010; Garbayo et al., 2013; Rocha, 2013; Cupaioli et al.,
2014] and a number of suitable and promising nanocarriers
have been identified (Fig. 1). Therefore, we only mention
some of the many recent examples highlighting the poten-
tial application of nanotechnology in diagnosis and treat-
ment of neurodegenerative diseases.
Due to their lipophilic nature, which allows them to
cross the BBB by passive diffusion [Brasnjevic et al.,
2009; Redzic et al., 2011], in the recent past nanolipidic
structures have been coupled to drugs and used for the
treatment of AD and PD. For instance, the encapsulation
of rivastigmine, an inhibitor of acetylcholinesterase
(AChE) and butyrylcholinesterase, into liposomes showed
potential therapeutic effects in an aluminium chloride-
induced Alzheimer’s rat model. The administration of
rivastigmine-loaded liposomes to AlCl3-treated rats nor-
malized expression of BACE1 (the gene coding for the b-
secretase which cleaves APP producing Ab peptides),
AChE (coding for the enzyme acetylcholinesterase which
inactivates the neurotransmitter acetylcholine by
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catalyzing its hydrolysis to choline and acetic acid), and
IL1B gene (coding for a member of the interleukin 1
cytokine family, mediator of the inflammatory response).
In contrast, co-treatment with rivastigmine solution
caused a significant down-regulation of these genes
[Ismail et al., 2013]. To overcome the poor bioavailability
and solubility of curcumin, a pleiotropic molecule with
anti-inflammatory and anti-oxidant activity, nanolipo-
somes loaded or functionalized with curcumin have been
designed. In vitro, curcumin liposomes showed very high
affinity [Mourtas et al., 2011] for Aß1–42 and inhibited its
aggregation [Taylor et al., 2011]. Moreover, Lazar et al.
[2013] demonstrated that mono-dispersed curcumin-conju-
gated nanoliposomes are biocompatible and bind selec-
tively to Aß1–42 deposits. In vitro these nanolipidic
structures were not toxic to HEK human embryonic kid-
ney and human neuroblastoma SHSY5Y cells and down-
regulated the secretion of the amyloid peptide. Ex vivo
they were reported to strongly bind to Aß1–42 deposits in
post-mortem brain tissue of AD patients, and in vivo they
specifically stained Aß1–42 in APPxPS1 mice, a transgenic
animal model of AD expressing mutant APP and preseni-
lin 1, both involved in Aß1–42 production. Furthermore,
anti-apoptotic and neurotrophic effects were demonstrated
in a rat model of PD by using liposomal-formulated cur-
cumin targeting histone deacetylase [Chiu et al., 2013].
Polymeric nanoparticles are stable NPs that are charac-
terized by high drug loading capacity and their ability to
protect the loaded drug against degradation, facilitating
its delivery to the CNS [Behan et al., 2001]. Poly(n-butyl-
cyanoacrylate) nanoparticles coated with 1% polysorbate
80 were shown to be more efficient in delivering rivastig-
mine into the brain of male Wistar rats than the free drug
[Wilson et al., 2008]. Orally administered Tween80-
coated polylactide-co-glycolide (PLGA) NPs containing
estradiol resulted in significantly higher brain estradiol
levels after 24 hr as compared with uncoated ones in an
ovariectomized rat model of AD [Mittal et al., 2011].
Moreover, the conjugation of polyethylene glycol-
polylactide-polyglycolide nanoparticles (PEG-PLGA NPs)
with lactoferrin was shown to facilitate NP internalization
in brain endothelial cells in vitro, and to enhance NPs
accumulation in an in vivo mice model of PD [Hu et al.,
2011]. Also in vivo, delivery of the human glial cell line-
derived neurotrophic factor gene hGDNF by loading it
into lactoferrin-modified PEG-PLGA NPs and injecting it
repeatedly into a PD rat model was shown to improve
locomotor activity, reduce dopaminergic neuronal loss
and enhance monoamine neurotransmitter levels [Huang
et al., 2009].
Among the inorganic NPs, IONPs are widely used in ther-
apeutic and diagnostic applications. IONPs, which depend-
ing on their size can be classified in superparamagnetic iron
oxide (SPIONs, 60–150 nm in diameter) and ultrasmall
superparamagnetic iron oxide (USPIONs, 10–40 nm), have a
Fe-core and can be coupled to organic materials and drugs.
USPIONs chemically coupled with Aß1–42 were proposed as
poorly invasive diagnostic tools for the in vivo detection of
amyloid plaques by magnetic resonance microimaging
[Yang et al., 2011]. Due to their increased relaxivity leading
to an improvement in the contrast of the image during MRI
and in vitro binding to ß-amiloid aggregates, SPIONs were
proposed as ultra-sensitive nanoprobes for AD imaging
[Zhou et al., 2014]. Several examples of nanovehicles to
carry monoclonal antibodies against Aß1–42 into the brain
have been recently developed as theranostic tools, some of
them also being able to carry conjugated drugs to the Aß
deposits [Poduslo et al., 2011; Agyare et al., 2014; Jaruszew-
ski et al., 2014]. Similarly, quantum dots proved to be highly
efficient to detect the potential AD biomarker
apolipoprotein-E [Morales-Narvaez et al., 2012], and
SWCNTs were reported to be able to deliver acethylcholine
in the brain of Kunming mice [Yang et al., 2010].
The treatment of neurodegenerative diseases is a major
challenge, both because suitable drugs have not yet been
identified for most diseases, and because of the limited
access of bulky molecules, such as peptides and proteins,
through the BBB. To overcome the latter problem, a grow-
ing number of nanotechnology-based delivery systems have
ben proposed that are likely to be useful for either the diag-
nosis or treatment of neurodegenerative disorders. Many
approaches are being tested with promising results, which
go beyond the limited number of examples shown here.
However, research into these materials is in its infancy.
Among the important issues to be taken into consideration
are the affinity between the drug and the nanobiocarrier
(whereas there are drugs still to be identified), and the sub-
sequent removal of the nanodevices from the brain.
CONCLUDING REMARKS
The ever-growing use of NMs in several human set-
tings, including medical applications, raises the question
Fig.1. The variety of materials of nanometric size summarized here may
be useful for the diagnosis and treatment of neurodegenerative diseases.
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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of the safety of humans employed in the manufacturing
of those materials and consumers of NMs-containing
products. In this regard, several authors have suggested
that NMs can be toxic to various human organs and sys-
tems, including the CNS, thereby potentially contributing
to the onset of human complex pathologies such as neuro-
degenerative diseases. On the other hand, the increasing
number of elderly people in both developed and develop-
ing countries, coupled with the fact that there is actually
no available treatment to halt the progression of most
neurodegenerative conditions, lead to projections that
those disorders will soon represent a serious health and
socio-economic concern, reinforcing the demand for early
diagnostic tools and novel therapeutic approaches. Nano-
technology has the possibility to impact both sides of this
same coin. NMs may contribute to the onset and progres-
sion of several human pathologies due to the toxic prop-
erties. Alternatively, the physico-chemical properties of
NMs make them important in the delivery of either diag-
nostic or therapeutic compounds to the site of disease
lesion that might be difficult to reach with other
methodologies.
In this review we presented an overview of studies that
assess the impact on the nervous system of some of the
most widespread nanoparticles. For in vitro approaches
various cell models have been used for the assessment of
neurotoxicity and of other related effects, representing the
main cell types composing the brain: neurons and neuro-
glial cells (oligodendrocytes, astrocytes, microglia) or
Schwann cells, responsible for the myelination of axons,
or endothelial cells, which compose the BBB. The main
cell lines employed were non-neuronal tumor cell lines
such as pheochromocytoma (PC12) cells and neuronal
tumor cell lines represented for instance by the human
neuroblastoma SHSY5Y. In other cases primary cells
obtained from mouse brain were used (mainly glial). For
in vivo studies many of the best known mammalian mod-
els (rat and mouse) have been employed, as well as the
invertebrate zebrafish (Danio rerio), including a transge-
nerational model. Among the in vivo experiments, differ-
ent routes and times of administration have been
employed. Almost all the reported studies clearly demon-
strate the potential for several NMs to reach the CNS and
induce toxic effects. Moreover, many NMs may interfere
with pathways including oxidative stress, genotoxicity,
apoptosis, inflammation, and microglia activation, which
are common to most of the human neurodegenerative dis-
orders, suggesting that they are able to contribute to
neurodegeneration.
However, it is hard to compare the studies, both for the
various cell models used, and for the different NMs
employed, which can differ in relation to chemical and
physical properties. For example, particle size can influ-
ence the behavior of the particle, that is, microsized NPs
are typically less active than nanosized ones. For
instance, micron-sized TiO2 did not induce toxicity in
PC12 cells, in contrast to nanosized TiO2 [Wu et al.,
2010]. Also smaller Ag NPs produced stronger inflamma-
tory responses correlated with increased cerebral micro-
vascular permeability compared with the larger ones in
primary rat brain microvessel endothelial cells [Trickler
et al., 2010]. Likewise, the influence of the size was
shown in vivo; in different animal models (mouse and
rat) smaller nano-sized Ag NPs internalize better and may
cause BBB damage, organ toxicity and inflammatory
response, in a size-dependent manner [Park et al., 2010;
Dziendzikowska et al., 2012; Sharma et al., 2013b]. Con-
versely, in some cases the small size did not aggravate
toxic effects, such as TiO2 when tested in human astrocy-
toman cells [Lai et al., 2008] or ZnO, when tested in
NSC mouse neural stem cells [Deng et al., 2009].
Even the NM shape can exert an influence on neurotox-
icity: ZnO nanoparticles and microspheres displayed signif-
icant cytotoxic effects on RSC96 rat Schwann cells in
dose- and time-dependent manners, while no or low cyto-
toxic effect was observed when the cells were treated with
the prism-like and flower-like ZnO [Yin et al., 2012]. The
surface modification of the NMs also seems to play a role
on their effects on the brain, as shown in the in vivo studies
of Zhang et al. [2011a, b, c] where mice were intranasally
instilled with four different types of TiO2 NPs varying in
size and coating. Hydrophobic particles without coating
resulted in less neurotoxicity than hydrophilic particles
with silica surface coating. Particular concern should be
devoted to metallic substances, which have the potential to
be taken up through airborne exposure and enter the brain
directly via retrograde transport through the olfactory
nerve. In the brain, NMs may induce inflammation, apopto-
sis and oxidative stress as accumulating evidence strongly
suggests that ROS generation and the induction of oxida-
tive stress is a major toxicological paradigm for engineered
metal oxide nanoparticles. For all the NMs considered in
this review it has been demonstrated that NMs deposited in
the nasal epithelium of animals may enter the brain via the
olfactory bulb. Another portal of entry of NMs to the brain
is from the systemic circulation. Neurotoxic effects
have also been demonstrated through other routes of
administration employed in the in vivo studies (e.g., oral,
intraperitoneal).
Considering all of the studies conducted so far, what
emerges is a deficiency in the use of models and standar-
dized methods. Standardized approaches are desirable in
NM research to ensure that the data can be used effec-
tively in risk assessment. The field can be improved by
introducing a concern-driven strategy for NMs potentially
at risk or employed for specific purposes in the area of
CNS [Oomen et al., 2013]. Moreover, it should be neces-
sary to take into account (as much as possible) the bio-
persistence and accumulation of NMs, as well as their
fate within critical tissues. In addition, the solubility
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should be taken into account when metal NPs are investi-
gated, highlighting the importance of including proper
controls in the experimental design, in order to discrimi-
nate between the toxicity triggered by the ionic part and
the effects induced by the particles themselves. It is desir-
able to develop new models, in line with the 3Rs princi-
ple (by using fewer animals, but obtaining more
information at the same time), as well as exploiting the
potential of emerging technology that employs iPSCs
(induced pluripotent stem cells, increasingly used as cell
model in vitro for neurodegenerative diseases), and the
inclusion of new endpoints (such as epigenetic marks).
Collectively the data indicate an obvious need for a
better assessment of the human risk of disease following
exposure to NMs, including a clarifying of our under-
standing on the impact of those NMs on the human body,
and their potential aggregation, accumulation, and targets.
This is particularly true for those compounds designed for
clinical applications or to be in direct contact with human
tissues, for which a careful assessment of the risk-benefit
ratio is compulsory. Drs. Migliore, Uboldi, Di Bucchia-
nico and Coppede` together researched, designed, and
wrote this review article.
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